Poseida Therapeutics Enters Research Collaboration With Takeda to Develop Novel Gene Therapies

Reston – November 17, 2021 – Cooley advised Poseida Therapeutics, a clinical-stage biopharmaceutical company, on its research collaboration and exclusive license agreement with Takeda Pharmaceutical Co. Lawyers Ken Krisko and Brendan Haberle led the Cooley team advising Poseida.

Under the terms of the agreement, the companies will collaborate to initially develop up to six in vivo gene therapy programs utilizing Poseida’s novel technology platforms, including piggyBac, Cas-CLOVER and biodegradable nanoparticle technology, as well as certain emerging technologies. Takeda also has an option to add two programs to the collaboration and is obligated to provide funding for all collaboration program research and development costs.

“We are excited to partner with Takeda, a global biopharmaceutical leader whose commitment to the development of novel therapies for rare diseases complements our innovative platform technologies and robust gene therapy pipeline,” Eric Ostertag, chief executive officer of Poseida, said in a news release. “Our technologies offer highly efficient gene delivery, fully integrated non-viral genome insertion and ultra-precise site-specific gene editing. Together with Takeda, we look forward to developing potential cures for a number of genetic diseases with high unmet need.”

Poseida will receive an upfront payment of $45 million and preclinical milestones that together could potentially exceed an aggregate of $125 million, if milestones for six programs are achieved, as well as future clinical development, regulatory and commercial milestone payments totaling up to $2.7 billion – and up to $3.6 billion for the two optional program milestones. The company will lead research activities up to candidate selection, after which Takeda will assume responsibility for further development and commercialization.

Founded in 2014, Poseida Therapeutics is dedicated to utilizing its proprietary genetic engineering platform technologies to create next-generation cell and gene therapeutics with the capacity to cure life-threatening diseases. Its core platform technologies have utility, alone or in combination, across many cell and gene therapeutic modalities, and enable the company to engineer its portfolio of product candidates designed to overcome the primary limitations of current cell and gene therapeutics.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.